Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

Abstract

A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver–chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: E2-specific human mAbs.

Similar content being viewed by others

References

  1. Pileri, P. et al. Science 282, 938–941 (1998).

    Article  CAS  Google Scholar 

  2. Cocquerel, L., Kuo, C.C., Dubuisson, J. & Levy, S. J. Virol. 77, 10677–10683 (2003).

    Article  CAS  Google Scholar 

  3. Wakita, T. et al. Nat. Med. 11, 791–796 (2005).

    Article  CAS  Google Scholar 

  4. Bartosch, B., Dubuisson, J. & Cosset, F.L. J. Exp. Med. 197, 633–642 (2003).

    Article  CAS  Google Scholar 

  5. Hsu, M. et al. Proc. Natl. Acad. Sci. USA 100, 7271–7276 (2003).

    Article  CAS  Google Scholar 

  6. Rosa, D. et al. Proc. Natl. Acad. Sci. USA 93, 1759–1763 (1996).

    Article  CAS  Google Scholar 

  7. Owsianka, A.M. et al. J. Virol. 80, 8695–8704 (2006).

    Article  CAS  Google Scholar 

  8. Kneteman, N.M. et al. Hepatology 43, 1346–1353 (2006).

    Article  CAS  Google Scholar 

  9. Lindenbach, B.D. et al. Proc. Natl. Acad. Sci. USA 103, 3805–3809 (2006).

    Article  CAS  Google Scholar 

  10. Keck, Z.Y. et al. J. Virol. 78, 9224–9232 (2004).

    Article  CAS  Google Scholar 

  11. Elmowalid, G.A. et al. Proc. Natl. Acad. Sci. USA 104, 8427–8432 (2007).

    Article  CAS  Google Scholar 

  12. Folgori, A. et al. Nat. Med. 12, 190–197 (2006).

    Article  CAS  Google Scholar 

  13. Tarr, A.W. et al. Hepatology 43, 592–601 (2006).

    Article  CAS  Google Scholar 

  14. Michalak, J.P. et al. J. Gen. Virol. 78, 2299–2306 (1997).

    Article  CAS  Google Scholar 

  15. Troesch, M. et al. Virology 352, 357–367 (2006).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

M.L. was an Elizabeth Glaser Pediatric AIDS Foundation Scholar. T.M. was supported in part by the Sjögren's Syndrome Foundation and Arthritis Foundation. N.M.K. was supported by a Senior Scholar award from the Alberta Heritage Foundation for Medical Research and a Wyeth Canada–Canadian Institutes for Health Research Clinical Research Chair in Transplantation. We thank A. Hessell for help in antibody production and P. Poignard for discussion. We acknowledge the generous gifts of J. Dubuisson (Institut Pasteur de Lille; mAbs A4 and H53), A. Patel (University of Glasgow; mAbs AP33, AP320 and ALP98), S. Foung (Stanford University; mAbs CBH-2, CBH-5, CBH-4B and CBH-7), S. Levy (Stanford University; GST-CD81-LEL), T. Wakita (Tokyo Metropolitan Institute for Neuroscience; JFH-1 cDNA) and J. Bukh (US National Institutes of Health; H77 and J6 cDNA). This is article 18887 from The Scripps Research Institute.

Author information

Authors and Affiliations

Authors

Contributions

M.L., N.M.K. and D.R.B. wrote the paper. T.M., R.I.F. and I.M.J. generated and panned the phage-display antibody library. M.L., E.G, Z.S, P.G., F.V.C. and J.A.M. performed the virus neutralization experiments and M.L., T.M., E.G., A.W.T. and J.K.B. performed the epitope mapping experiments. The mouse experiments and quantitative PCR were conducted by J.L. and N.M.K. and the downstream immunological and virus neutralization assays were performed by M.L. and E.G.

Corresponding authors

Correspondence to Norman M Kneteman or Dennis R Burton.

Ethics declarations

Competing interests

Norman M. Kneteman is an officer and stockholder with KMT Hepatech, Inc., which owns the SCID/uPA chimeric mouse model.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–8 and Supplementary Methods (PDF 369 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Law, M., Maruyama, T., Lewis, J. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14, 25–27 (2008). https://doi.org/10.1038/nm1698

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1698

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing